Metformin therapy and its anti-neoplastic role in systemic malignancies besides hepatocellular carcinomas

S. Kapoor

DOI: https://doi.org/10.3109/00365521.2013.777773

2013-04-18

Scandinavian Journal of Gastroenterology

Abstract:To the Editor: I read with great interest the recent article written by Zhang et al. [1]. Suggest that metformin may play a major role in mitigating carcinogenesis as well as in enhancing the efficacy of chemotherapeutic agents in other systemic malignancies besides hepatocellular carcinomas. For instance, in vivo growth of ovarian carcinomas stem cells is inhibited by administration of metformin. In fact when used with chemotherapeutic agents such as cisplatin, it shows a synergistic effect, as the efficacy of cisplatin to decrease tumor proliferation is significantly enhanced [2]. A simultaneous decrease in angiogenesis is also seen. Similarly, ovarian resistance to cisplatin chemotherapy can be overcome using alternative regimens such as metformin therapy in conjunction with phenethyl isothiocyanate therapy [3]. Similarly, metformin attenuates the risk of developing distant metastasis in patients with ovarian malignancies. Decreased cellular/extracellular matrix interactions as well as attenuated expression of vWF contribute to this decreased risk of metastasis [4]. Tumor growth in cervical carcinomas is also attenuated by metformin therapy by virtue of enhancement of autophagy as well as intra-cervical apoptosis. This is especially so in cervical carcinoma cells that expresses LKB1 and thereby can demonstrate an AMPK-mTOR response [5]. Not surprisingly, decreased response to metformin therapy is seen following LKB1 knockdown. Similarly, metformin attenuates the expression of glyoxalase I and thereby enhances the chemo-sensitivity of endometrial carcinomas [6]. Similarly, metformin influences tumor formation in the colon. For instance, the incidence of benign colorectal polyps in diabetic patients with a prior history of colorectal carcinoma is significantly reduced following therapy with metformin. For instance, in a recent study, the incidence of colorectal adenomas was 56% in the non-metformin group compared to 29% in the metformin group [7]. Similarly, an almost 60% decline in the risk for cholangio-carcinomas is seen in diabetic patients on metformin therapy [8]. Similarly, the risk of developing pulmonary malignancies is much lower in diabetic patients on metformin therapy. Those who develop lung cancers even on metformin therapy tend to have more aggressive tumors with higher metastasis as well as decreased survival rates [10]. Metformin has a negative impact on tumor clonogenicity and also causes cytostasis. Enhancement of apoptosis is usually most marked in small cell carcinomas resulting in an increase in G0/G1 phase cells. Similarly, metformin is of considerable benefit in the management of prostatic malignancies. For instance, the apoptotic effect of agents such as bicalutamide is enhanced following the initiation of adjunctive metformin therapy in androgen negative prostate cancers. On the other hand, the intraprostatic proliferation is attenuated in androgen receptor positive malignancies [11]. There is also accentuated expression of Bcl-2-associated X protein, and an increase in G1/S phase arrest is typically seen [12]. The examples given previously clearly illustrate the significance of metformin in oncology and the need for further studies in this regard.